Having trouble accessing articles? Reset your cache.

Tenofovir alafenamide fumarate: Additional Phase II data

Additional data from the double-blind, U.S. Phase II Study 102 trial in 170 treatment-naïve patients with HIV-1 infection showed that once-daily TAF/elvitegravir/cobicistat/emtricitabine increased mean CD4 cell count from baseline to week 24 by 163 cells/mm 3 vs. 177 cells/mm 3 for Gilead's Stribild elvitegravir/cobicistat/emtricitabine/tenofovir (p=0.76). The TAF-based regimen

Read the full 480 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE